The Phase 2 JAVELIN Merkel 200 study showed an overall response rate (ORR) of 39.7% in 116 treatment-naïve patients with metastatic MCC treated with the PD-L1 inhibitor avelumab. This evidence concerns the gene CD274 and Merkel cell skin cancer.